Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 30;30(11):2406.
doi: 10.3390/molecules30112406.

Bactericidal Effect of Synthetic Phenylalkylamides Inspired by Gibbilimbol B Against Neisseria gonorrhoeae

Affiliations

Bactericidal Effect of Synthetic Phenylalkylamides Inspired by Gibbilimbol B Against Neisseria gonorrhoeae

Larissa V F Oliveira et al. Molecules. .

Abstract

Increasing multidrug resistance in Neisseria gonorrhoeae poses a serious and escalating public health crisis. The World Health Organization has classified N. gonorrhoeae as a high-priority pathogen for developing new antimicrobials. Natural products provide a promising avenue for antimicrobial discovery, serving as direct therapeutic agents or prototypes for novel drug development. Among these, gibbilimbol B, a compound isolated from Piper malacophyllum, is particularly attractive due to its biological potential and simple structure. In this study, eight synthetic phenylalkylamides (1-8) inspired by gibbilimbol B were synthesized and evaluated for their antibacterial activity against N. gonorrhoeae. The in vitro bacterial assays revealed that these compounds exhibit notable antibacterial activity, including against resistant strains selected from the CDC/FDA antimicrobial panel (strains AR-173, AR-174, AR-187, and AR-200). All synthesized compounds demonstrated superior efficacy in killing N. gonorrhoeae compared to gibbilimbol B. Notably, compound 8 [(E)-4-chloro-N-(oct-4-en-1-yl)benzamide] showed an MBC50 of 6.25 µM, representing a four-fold improvement in bactericidal activity over the natural compound. This study represents the first exploration of gibbilimbol analogs for antibacterial applications, highlighting the novelty of the work and paving the way for the development of new antibacterial agents.

Keywords: Neisseria gonorrhoeae; analogs; bactericidal; gibbilimbol B; natural products.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Chemical structure of gibbilimbol B.
Figure 2
Figure 2
Illustration of the schematic procedure employed in the synthesis of the amides 18. (a) Reaction with 1-octylamine; (b) reaction with (E)-oct-4-en-1-amine. Reaction conditions: CH2Cl2, 0 °C, N2 atmosphere, Et3N.
Figure 3
Figure 3
The bactericidal activity of gibbilimbol analogs 18 (blue) and ceftriaxone (CEF) (black) at 50 µM, assessed by viable counting in the bactericidal assay. The columns represent the mean % killing, and the error bars indicate the standard error of the mean (SEM) from four independent experiments (n = 4).
Figure 4
Figure 4
Heatmap showing the percentage of N. gonorrhoeae P9-17 killing at different concentrations (1.5625 to 50 µM) of gibbilimbol analogs 28. Data represent the mean of three independent experiments, each performed in triplicate.

Similar articles

References

    1. Murray C.J., Ikuta K.S., Sharara F., Swetschinski L., Robles Aguilar G., Gray A., Han C., Bisignano C., Rao P., Wool E., et al. Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis. Lancet. 2022;399:629–655. doi: 10.1016/S0140-6736(21)02724-0. - DOI - PMC - PubMed
    1. WHO . Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report 2022. World Health Organization; Geneva, Switzerland: 2022.
    1. World Health Organization . WHO Bacterial Priority Pathogens List, 2024: Bacterial Pathogens of Public Health Importance to Guide Research, Development and Strategies to Prevent and Control Antimicrobial Resistance. WHO; Geneva, Switzerland: 2024.
    1. World Health Organization WHO Publishes List of Bacteria for Which New Antibiotics Are Urgently Needed. [(accessed on 19 February 2023)]. Available online: https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-....
    1. Raccagni A.R., Ranzenigo M., Bruzzesi E., Maci C., Castagna A., Nozza S. Antimicrobial Resistance: The Future of Antibiotic Therapy. J. Clin. Med. 2023;12:7767. doi: 10.3390/jcm12247767. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources